Medicenna Therapeutics (TSX:MDNA) - Cotización, noticias y análisis

Resumen de acción MDNA

Medicenna Therapeutics Corp., una empresa de inmunoterapia, se dedica al desarrollo y comercialización de Superkines y Superkines potenciadas para el tratamiento del cáncer y otras enfermedades.

Acerca de la empresa

MDNA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 61.31%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (CA$0)

Alta volatilidad del precio de la acción en los últimos 3 meses

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Medicenna Therapeutics Corp.

Eupraxia Pharmaceuticals

TSX:EPRX

CA$140.4m

Sernova

TSX:SVA

CA$121.4m

Oncolytics Biotech

TSX:ONC

CA$120.7m

Helix BioPharma

TSX:HBP

CA$48.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Medicenna Therapeutics
Historical stock prices
Current Share Price	CA$2.39
52 Week High	CA$2.68
52 Week Low	CA$0.21
Beta	1.33
1 Month Change	45.73%
3 Month Change	443.18%
1 Year Change	136.63%
3 Year Change	-46.41%
5 Year Change	236.62%
Change since IPO	-11.48%

Noticias y actualizaciones recientes

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Rentabilidad de los accionistas

	MDNA	CA Biotechs	Mercado CA
7D	-4.0%	-3.4%	-0.1%
1Y	136.6%	-39.7%	6.2%

Rentabilidad vs. Industria: MDNA superó al sector Canadian Biotechs , que obtuvo un rendimiento del -36.8% el año pasado.

Rentabilidad vs. Mercado: MDNA superó al mercado Canadian, que obtuvo un rendimiento del 5.5% el año pasado.

Volatilidad de los precios

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement	23.1%
Biotechs Industry Average Movement	11.7%
Market Average Movement	8.9%
10% most volatile stocks in CA Market	18.1%
10% least volatile stocks in CA Market	3.1%

Precio estable de las acciones: El precio de las acciones de MDNA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MDNA ha aumentado de 18% a 23% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	16	Fahar Merchant	www.medicenna.com

Medicenna Therapeutics Corp., empresa de inmunoterapia, se dedica al desarrollo y comercialización de supercinas y supercinas potenciadas para el tratamiento del cáncer y otras enfermedades. Desarrolla MDNA55, un CE de interleucina 4 (IL-4) para el tratamiento del glioblastoma recurrente, así como para tumores cerebrales. La empresa también desarrolla MDNA11, una versión mejorada de IL-2 para activar y proliferar las células inmunitarias necesarias para combatir el cáncer; MDNA209, un antagonista de IL-2 para enfermedades autoinmunes, como la esclerosis múltiple y la enfermedad de injerto contra huésped; MDNA413, un antagonista dual IL-4/IL-13 para tratar inmunoterapias contra el cáncer; y MDNA132, una superquina IL-13 para tumores sólidos.

Resumen de fundamentos de Medicenna Therapeutics Corp.

¿Cómo se comparan los beneficios e ingresos de Medicenna Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de MDNA
Capitalización bursátil	CA$178.72m
Beneficios(TTM)	-CA$15.42m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-11.6x

Ratio precio-beneficio (PE)

¿Está MDNA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MDNA
Ingresos	CA$0
Coste de los ingresos	CA$0
Beneficio bruto	CA$0
Otros gastos	CA$15.42m
Beneficios	-CA$15.42m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.21
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado MDNA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MDNA

Recompensas

Análisis de riesgos

Competidores de Medicenna Therapeutics Corp.

TSX:EPRX

CA$140.4m

TSX:SVA

CA$121.4m

TSX:ONC

CA$120.7m

TSX:HBP

CA$48.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Recent updates

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Medicenna Therapeutics Corp. Announces Board Appointments

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada